Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY26 results · Oct–Dec 2025
Astec LifeSciences reported revenue from operations of ₹124.72 crore (up 32.9% from Q3 FY25) and net loss of ₹15.69 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.72 | 93.86 | +32.9% | 73.72 | +69.2% |
| Other income | 0.82 | 1.91 | −57.4% | 1.12 | −26.9% |
| Total income | 125.54 | 95.77 | +31.1% | 74.84 | +67.7% |
| Profit before tax | (15.68) | (25.15) | Loss narrowed | (24.41) | Loss narrowed |
| Net profit for the period | (15.69) | (40.37) | Loss narrowed | (24.42) | Loss narrowed |
| Attributable to shareholders of the company | (15.70) | (40.38) | Loss narrowed | (24.43) | Loss narrowed |
| EPS, basic (₹) | (7.04) | (20.59) | not comparable | (11.35) | Loss narrowed |
| Net margin (%) | -12.6 | -43.0 | -33.1 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.72 | 93.86 | +32.9% | 73.72 | +69.2% |
| Other income | 0.79 | 1.89 | −58.1% | 1.09 | −27.5% |
| Total income | 125.51 | 95.75 | +31.1% | 74.81 | +67.8% |
| Profit before tax | (15.72) | (25.18) | Loss narrowed | (24.45) | Loss narrowed |
| Net profit for the period | (15.72) | (40.40) | Loss narrowed | (24.45) | Loss narrowed |
| EPS, basic (₹) | 7.06 | (20.60) | not comparable | (11.39) | Turned profit |
| Net margin (%) | -12.6 | -43.0 | -33.2 |
Consolidated
- Filed with BSE
- 30 Jan 2026, 20:35 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2026, 20:35 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE